Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5289

Shown on this page

Current sort

How Leukemia studies are organized in the registry

“Leukemia” is an umbrella term; in practice most records name the specific subtype, and this directory has dedicated pages for the major ones — acute myeloid (AML), chronic lymphocytic (CLL), and acute lymphoblastic (ALL) leukemia. Use this page when scanning across subtypes, and the subtype pages when you know which disease you mean.

Terms that often appear in related listings

AML CLL ALL CML relapsed refractory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 241–252 of 5,289 matching trials for Leukemia.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Acute Lymphocytic Leukemia, Lymphoma
Interventions: Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Interventions: Zilovertamab vedotin; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Months to 25 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: DMSA, Ca-EDTA, Magnesium Sulfate, Multivitamin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia
Interventions: Acalabrutinib, Venetoclax, Chemoimmunotherapy, Obinutuzumab; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Redondo Beach, California • Fort Wayne, Indiana + 12 more

Conditions: Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Interventions: no intervention; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: All Conditions, All
Interventions: Not listed
Lead sponsor: Head Diagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia • Cambridge, Massachusetts

Conditions: Acute Myeloid Leukemia
Interventions: Pivekimab Sunirine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Palo Alto, California • Atlanta, Georgia • Valhalla, New York + 2 more

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm
Interventions: Azacitidine, Quizartinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia
Interventions: CAR T cell therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Durvalumab, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Positron Emission Tomography (PET), Computed Tomography; Drug · Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: Fludarabine, Cyclophosphamide, CAR-T; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

About this Leukemia clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Leukemia clinical trials

How Leukemia studies are organized in the registry

Filter and sort this condition

Live official records

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

About this Leukemia clinical trials directory page